Highnoon Laboratories Limited (PSX:HINOON)

Pakistan · Delayed Price · Currency is PKR

970.13

-7.89 (-0.81%)

At close: Nov 6, 2026

Market Cap	51.40B -13.0%
Revenue (ttm)	28.89B +9.4%
Net Income	4.16B +20.3%
EPS	78.55 +20.3%
Shares Out	52.98M
PE Ratio	12.35
Forward PE	11.75
Dividend	50.00 (5.15%)
Ex-Dividend Date	Apr 22, 2026

Volume	4,779
Open	978.03
Previous Close	978.02
Day's Range	951.30 - 978.03
52-Week Range	755.56 - 1,150.00
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiary, engages in the development, production, marketing, and distribution of pharmaceutical and allied consumer products in Pakistan, Afghanistan, the United Arab Emirates, Sri Lanka, France, Sudan, Cambodia, Kenya, Iraq, Dubai, Tanzania, and internationally. The company offers medicines in various drug forms and brands for allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynecology, pediatrics, respiratory, and urology therapeutic areas. It ... [Read more]

Industry Pharmaceuticals

Sector Healthcare

Founded 1984

Employees 2,563

Stock Exchange Pakistan Stock Exchange

Ticker Symbol HINOON

Full Company Profile

Financial Performance

In 2025, Highnoon Laboratories's revenue was 27.71 billion, an increase of 12.44% compared to the previous year's 24.64 billion. Earnings were 4.13 billion, an increase of 21.83%.

Financial Statements